Clinical Trial Update: Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial evaluated vinpocetine for reducing NF-κB–dependent inflammation in patients with acute ischemic stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Vinpocetine (vinpocetine)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Stroke, Immunoregulation | Phase 2, Phase 3 | Status: COMPLETED